tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate | 130466-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate
• 英文别名: tricyclo<3.3.1.1^3,7>dec-2-yl (+/-)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<(2-phenylethyl)amino>ethyl>carbamate；tricyclo<3.3.1.1^3,7>dec-2-yl (RS)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<(2-phenylethyl)amino>ethyl>carbamate；tricyclo<3.3.1.1^3,7>dec-2-yl(RS)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<(2-phenylethyl)amino>ethyl>carbamate；N--DL-α-methyltryptophanyl>-2-phenylethylamine；(+/-)-tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate；(+/-)-tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate；[2-(1H-Indol-3-yl)-1-methyl-1-phenethylcarbamoyl-ethyl]-carbamic acid adamantan-2-yl ester；2-adamantyl N-[3-(1H-indol-3-yl)-2-methyl-1-oxo-1-(2-phenylethylamino)propan-2-yl]carbamate
• CAS: 130466-73-8
• 化学式: C₃₁H₃₇N₃O₃
• 分子量: 499.653
• InChiKey: RGFJPHVCLXSEHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  83.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-金刚烷醇 在 吡啶 、 lithium hydroxide 、 五氟苯酚 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 86.25h， 生成 tricyclo[3.3.1.13,7 ]dec-2-yl [1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]-ethyl]carbamate
  参考文献：
  名称：

  合理设计CCK的“二肽”类似物。α-甲基色氨酸衍生物，具有高度的抗焦虑特性，是具有高选择性和口服活性的胃泌素和CCK-B拮抗剂。

  摘要：

  本文介绍了合成和结构-活性关系（SAR），从而导致了神经肽胆囊收缩素（CCK）的“二肽”类似物的第一个合理设计。化合物[R-（R *，S *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧代-2-[（三环[3.3.1.1（3 ，7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -3-苯基丙基]-氨基] -4-氧代-2-丁烯酸，[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧-2-（[三环[3.3.1.1（3,7）]癸-2-氧）羰基]氨基]丙基]氨基] -1-苯乙基]氨基] -4-氧代-2-丁烯酸和[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基） -2-甲基-1-氧代-2-[（（三环[3.3.1.1（3,7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -1-苯基乙基]氨基] -4-氧代丁酸（29d）的CCK-B结合亲和力IC50

  DOI：

  10.1021/jm00105a062

文献信息

• Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and mixed CCK-A/CCK-B antagonists
  作者：P. R. Boden、M. Higginbottom、D. R. Hill、D. C. Horwell、J. Hughes、D. C. Rees、E. Roberts、L. Singh、N. Suman-Chauhan、G. N. Woodruff

  DOI：10.1021/jm00057a005

  日期：1993.3

  The design, synthesis, and structure-activity relationships (SAR) for the development of selective dipeptoid ligands for both of the cholecystokinin (CCK) receptor subtypes CCK-A and CCK-B are described. The SAR developed is used to design a ligand with equal nanomolar binding affinity for both the CCK-A and CCK-B receptors. Example compounds such as [1R-[1 alpha[R*(R*)],2 beta]]-4-[[2-[[3-(1H-indol-3-yl)-

  描述了开发胆囊收缩素（CCK）受体亚型CCK-A和CCK-B的选择性二肽配体的设计，合成和结构活性关系（SAR）。开发的SAR用于设计对CCK-A和CCK-B受体均具有相同纳摩尔结合亲和力的配体。示例化合物，例如[1R- [1 alpha [R *（R *）]，2 beta]]-4-[[2-[[3-（1H-吲哚-3-基）-2-甲基-2- [[[（（2-甲基环己基）氧基]羰基]氨基] -1-氧丙基]-氨基] -1-苯基乙基]氨基] -4-氧代丁酸（24c），（1R-反式）-N-α -甲基-N-[[（（2-甲基环己基）氧基]羰基] -D-色氨酸] -L-3-（苯甲基）-β-丙氨酸（28i）和N- [α-甲基-N-[（三环） [3.3.1.1]癸-2-基氧基）羰基] -D-色氨酸] -L-3-（苯甲基）-β-丙氨酸（30m）是具有CCK-B结合亲和力为IC50 = 3.9的CCK-B选择性化合物，
• Rationally designed "dipeptoid" analogs of CCK. .alpha.-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties
  作者：David C. Horwell、John Hughes、John C. Hunter、Martyn C. Pritchard、Reginald S. Richardson、Edward Roberts、Geoffrey N. Woodruff

  DOI：10.1021/jm00105a062

  日期：1991.1

  This paper describes the synthesis and structure-activity relationships (SAR) leading to the first rational design of "dipeptoid" analogues of the neuropeptide cholecystokinin (CCK). Compounds [R-(R*,S*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-3- phenylpropyl]-amino]-4-oxo-2-butenoic acid, [R-(R*,R*)]-4-[2-[3-(1H-indol-3-yl)-2-met

  本文介绍了合成和结构-活性关系（SAR），从而导致了神经肽胆囊收缩素（CCK）的“二肽”类似物的第一个合理设计。化合物[R-（R *，S *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧代-2-[（三环[3.3.1.1（3 ，7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -3-苯基丙基]-氨基] -4-氧代-2-丁烯酸，[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧-2-（[三环[3.3.1.1（3,7）]癸-2-氧）羰基]氨基]丙基]氨基] -1-苯乙基]氨基] -4-氧代-2-丁烯酸和[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基） -2-甲基-1-氧代-2-[（（三环[3.3.1.1（3,7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -1-苯基乙基]氨基] -4-氧代丁酸（29d）的CCK-B结合亲和力IC50
• Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis, and in vitro and in vivo biochemical properties
  作者：Armand G. S. Blommaert、Jian Hui Weng、Agnes Dorville、Isabelle McCort、Bertrand Ducos、Christine Durieux、Bernard P. Roques

  DOI：10.1021/jm00072a005

  日期：1993.10

  Antagonists of cholecystokinin-B (CCK-B) receptors have been shown to alleviate CCK4-induced panic attacks in humans and to potentiate opioid effects in animals. The clinical use of these compounds is critically dependent on their ability to cross the blood-brain barrier. In order to improve this property, new, peptoid-derived CCK-B antagonists, endowed with high affinity, selectivity, and increased lipophilicity have been developed. The affinity and selectivity of these compounds have been characterized in vitro and in vivo using guinea pig, rat, and mouse. Most of these compounds proved to be selective for the CCK-B receptor, the most potent analog, N-[N-[(2-adamantyloxy)carbonyl]-D-alpha-methyltryptophanyl]-N-[2-(4-chlorophenyl)ethyl]glycine (26A), having a K(i) value of 6.1 nM for guinea pig cortex membranes in vitro and a good selectivity ratio (K(i) CCK-A/K(i) CCK-B = 174). Furthermore, the in vivo affinity of 26A for mouse brain CCK-B receptors, following intracerebroventricular injection at different concentrations, was found to be 10 nmol. Using competition experiments with the specific CCK-B ligand [H-3]pBC 264, compound 26A was shown to cross the blood-brain barrier (0.2%) after intraperitoneal administration in mice. This compound is therefore an interesting pharmacological tool to further elucidate the physiopathological role of endogenous CCK.
• HORWELL, DAVID C.;HUGHES, JOHN;HUNTER, JOHN C.;PRITCHARD, MARTYN C.;RICHA+, J. MED. CHEM., 34,(1991) N, C. 404-414
  作者：HORWELL, DAVID C.、HUGHES, JOHN、HUNTER, JOHN C.、PRITCHARD, MARTYN C.、RICHA+

  DOI：——

  日期：——
• Rationally designed ‘dipeptoid’ analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyl-tryptophan derivatives
  作者：JM Eden、M Higginbottom、DR Hill、DC Horwell、JC Hunter、K Martin、MC Pritchard、SS Rahman、RS Richardson、E Roberts

  DOI：10.1016/0223-5234(93)90077-r

  日期：1993.1

  The structure-affinity relationships (SAR) between the N-terminii of a series of alpha-methyl-tryptophanylphenethylamide derivatives and the cholecystokinin (CCK) B receptor are discussed. A series of compounds with the general formula R-X-alpha-methyl-tryptophanylphenethylamide was prepared, where R is a cycloalkyl, a bicycloalkyl or a tricycloalkyl group and X is a urethane, thiourethane, amide, urea or a sulphinamide linking group. The CCK-B receptor binding affinities of these are discussed. The SAR form part of a systematic program for the rational design of 'dipeptoid' analogues of the neuropeptide CCK. Beginning with 1,1-dimethylpropyl (+/-)-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate (IC50 = 4720 nM on CCK-B binding affinity) the N-terminal moiety was systematically changed for groups of varying size, shape and lipophilicity until the optimal N-terminal group was obtained and the favoured linking group chosen, resulting in the compound tricyclo[3.3.1.1(3,7)]dec-2-yl(R)-[(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate with an IC50 = 32 nM on CCK-B receptor binding affinity.